Studies on the pharmacokinetics of piperacillin/tazobactam in renal replacement therapy in patients with chronic renal failure


 Purpose: To study the pharmacokinetics of piperacillin/tazobactam in renal replacement therapy (CRRT) patients with chronic failure (CRF).
 Methods: Six CRF treated CRRT First Affiliated Hospital Hebei North University from April 2020 to July were selected and administered 4 g piperacillin 0.5 tazobactam within 30 min after, at 5, 30, 45, 60, 90, 120, 180, 240, 360 480 after CRRT. The DAS software was used calculate pharmacokinetic parameters while linear regression analyze relationship among patient characteristics, parameters, pharmacokinetics.
 Results: Cmax 118.46 (96.12 - 161.12) mg/L 27.45 (14.75 28.45) mg/L, volume distribution (Vd) 1.16 (0.72 1.59) L/h 0.72 (0.57 -0.82) L/kg, respectively. value for elimination half-life (t1/2) 4.66 (3.19 -8.45) h 4.25 (3.42 5.96) h, total clearance (CL) 7.28 (5.58 9.73) 6.37 (4.28 10.04) L/h, Multivariate showed that negatively correlated flow velocity substitution fluid (β = -0.679, 95 % CI -0.278 0.943, p < 0.001). Piperacillin CL positively waste liquid 0.956, 1.267 4.796, 0.001).
 Conclusion: When receiving CRRT, show decrease CL, but increase t1/2. This finding should provide useful guidance clinicians concerned.